Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Pfizer License Agreement	Common Stock	Common Stock Pfizer License Agreement	Additional Paid-in Capital	Additional Paid-in Capital Pfizer License Agreement	Accumulated Deficit	Accumulated Other Comprehensive Income
Beginning balance at Dec. 31, 2021	$ 261,313		$ 32		$ 352,999		$ (91,718)
Beginning Balance, Shares at Dec. 31, 2021			32,222,881
Stock options exercised	176				176
Stock options exercised (Shares)			51,118
Vesting of restricted common stock	1				1
Vesting of restricted common stock (Shares)			100,908
Stock-based compensation	3,404				3,404
Net loss	(31,380)						(31,380)
Ending balance at Mar. 31, 2022	233,514		$ 32		356,580		(123,098)
Ending balance (in shares) at Mar. 31, 2022			32,374,907
Beginning balance at Dec. 31, 2022	$ 160,824		$ 34		373,225		(212,435)
Beginning Balance, Shares at Dec. 31, 2022			34,958,730
Issuance of common stock		$ 5,000		$ 2		$ 4,998
Issuance of common stock (Shares)				1,811,594
Stock options exercised (Shares)	0
Vesting of restricted common stock	$ 2		$ 1		1
Vesting of restricted common stock (Shares)			148,047
Stock-based compensation	4,884				4,884
Net unrealized gains on marketable debt securities	696							$ 696
Net loss	(19,243)						(19,243)
Ending balance at Mar. 31, 2023	$ 152,163		$ 37		$ 383,108		$ (231,678)	$ 696
Ending balance (in shares) at Mar. 31, 2023			36,918,371